KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Capital Expenditures (2016 - 2025)

Quest Diagnostics' Capital Expenditures history spans 15 years, with the latest figure at $123.0 million for Q4 2024.

  • For Q4 2024, Capital Expenditures rose 70.83% year-over-year to $123.0 million; the TTM value through Dec 2024 reached $425.0 million, up 4.17%, while the annual FY2024 figure was $425.0 million, 4.17% up from the prior year.
  • Capital Expenditures for Q4 2024 was $123.0 million at Quest Diagnostics, up from $106.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $162.0 million in Q4 2020 and bottomed at $72.0 million in Q4 2023.
  • The 4-year median for Capital Expenditures is $98.0 million (2023), against an average of $103.4 million.
  • The largest annual shift saw Capital Expenditures surged 76.6% in 2020 before it decreased 18.11% in 2024.
  • A 4-year view of Capital Expenditures shows it stood at $162.0 million in 2020, then fell by 11.11% to $144.0 million in 2021, then crashed by 50.0% to $72.0 million in 2023, then soared by 70.83% to $123.0 million in 2024.
  • Per Business Quant, the three most recent readings for DGX's Capital Expenditures are $123.0 million (Q4 2024), $106.0 million (Q3 2024), and $92.0 million (Q2 2024).